Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cartesian Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -10283.8%. For fiscal 2025 it was -4658.6%, against -199.0% the year before. The highest annual figure on record is 31.9% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4658.6% | −4459.7 |
| FY2024 | Dec 31, 2024 | -199.0% | +645.9 |
| FY2023 | Dec 31, 2023 | -844.9% | −876.8 |
| FY2022 | Dec 31, 2022 | 31.9% | +62.1 |
| FY2021 | Dec 31, 2021 | -30.2% | +384.8 |
| FY2020 | Dec 31, 2020 | -415.0% | +414.0 |
| FY2019 | Dec 31, 2019 | -829.0% | +6406.5 |
| FY2018 | Dec 31, 2018 | -7235.4% | +24320.6 |
| FY2017 | Dec 31, 2017 | -31556.0% | −31108.1 |
| FY2016 | Dec 31, 2016 | -448.0% | −29.2 |
| FY2015 | Dec 31, 2015 | -418.8% | +4.9 |
| FY2014 | Dec 31, 2014 | -423.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -50233.3% | −48623.3 |
| Q4 FY2025 | Dec 31, 2025 | -9775.7% | −3526.9 |
| Q3 FY2025 | Sep 30, 2025 | -7942.9% | −7984.3 |
| Q2 FY2025 | Jun 30, 2025 | 5330.9% | +6303.9 |
| Q1 FY2025 | Mar 31, 2025 | -1610.0% | +539.3 |
| Q3 FY2024 | Sep 30, 2024 | -6248.8% | −6111.4 |
| Q2 FY2024 | Jun 30, 2024 | 41.4% | +258.3 |
| Q1 FY2024 | Mar 31, 2024 | -973.0% | −608.2 |
| Q4 FY2023 | Dec 31, 2023 | -2149.3% | −2184.3 |
| Q3 FY2023 | Sep 30, 2023 | -137.4% | −99.3 |
| Q2 FY2023 | Jun 30, 2023 | -216.9% | −238.8 |
| Q1 FY2023 | Mar 31, 2023 | -364.8% | −449.5 |
| Q4 FY2022 | Dec 31, 2022 | 35.1% | −5.8 |
| Q3 FY2022 | Sep 30, 2022 | -38.1% | +35.1 |
| Q2 FY2022 | Jun 30, 2022 | 21.9% | −1.3 |
| Q1 FY2022 | Mar 31, 2022 | 84.6% | +307.2 |
| Q4 FY2021 | Dec 31, 2021 | 40.9% | +170.1 |
| Q3 FY2021 | Sep 30, 2021 | -73.3% | +136.2 |
| Q2 FY2021 | Jun 30, 2021 | 23.2% | +247.0 |
| Q1 FY2021 | Mar 31, 2021 | -222.6% | +125885.1 |
| Q4 FY2020 | Dec 31, 2020 | -129.2% | +120610.8 |
| Q3 FY2020 | Sep 30, 2020 | -209.4% | +1413.1 |
| Q4 FY2019 | Dec 31, 2019 | -223.7% | +114741.0 |
| Q2 FY2019 | Jun 30, 2019 | -126107.7% | −71752.1 |
| Q1 FY2019 | Mar 31, 2019 | -120740.0% | −59328.5 |
| Q4 FY2018 | Dec 31, 2018 | -1622.5% | +9424.2 |
| Q4 FY2017 | Dec 31, 2017 | -114964.7% | −114484.1 |
| Q3 FY2017 | Sep 30, 2017 | -54355.6% | −53618.2 |
| Q2 FY2017 | Jun 30, 2017 | -61411.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -11046.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -480.6% | – |
| Q3 FY2016 | Sep 30, 2016 | -737.4% | – |
See a number that looks wrong?